中文名稱:對照抗體 | 英文名稱:Research Grade Erlizumab |
CAS:211323-03-4 | 純度規(guī)格: 95% PAGE |
產(chǎn)品類別: 藥物對照抗體 | |
抗體名: Research Grade Erlizumab | 靶點: Complement receptor C3 subunit beta, Cell surface adhesion glycoproteins LFA-1/CR3/p150,95 subunit beta, Integrin beta-2, MFI7, CD18, ITGB2 |
宿主: Humanized | 適應(yīng)物種: Human |
克隆性: Monoclonal | 藥物對照抗體: Research Grade Erlizumab |
Catalog No.
DHC13101
Host species
Humanized
Species reactivity
Human
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Concentration
1 mg/ml
Purity
>95% by SDS-PAGE.
Clonality
Monoclonal
Isotype
IgG1-nd
Applications
Research Grade Biosimilar
Target
Complement receptor C3 subunit beta, Cell surface adhesion glycoproteins LFA-1/CR3/p150,95 subunit beta, Integrin beta-2, MFI7, CD18, ITGB2
Purification
Protein A or G purified from cell culture supernatant.
Endotoxin level
Please contact with the lab for this information.
Expression system
XtenCHO
Accession
P05107
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
Alternative Names
rhuMAb, CAS: 211323-03-4
Note
For research use only. Not suitable for clinical or therapeutic use.
成立日期 | 2021-04-08 (4年) | 注冊資本 | 700萬 |
員工人數(shù) | 100-500人 | 年營業(yè)額 | ¥ 1000萬-5000萬 |
主營行業(yè) | 生物化工,技術(shù)服務(wù) | 經(jīng)營模式 | 試劑 |
產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
---|---|---|---|---|
詢價 |
北京裕恒豐科技有限公司
|
2025-01-17 | ||
詢價 |
VIP4年
|
上海優(yōu)寧維生物科技股份有限公司
|
2025-01-22 | |
詢價 |
VIP4年
|
湖北魏氏化學(xué)試劑股份有限公司
|
2025-01-23 |